{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:21:55Z","timestamp":1789237315246,"version":"build-2803163510"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Surg"],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"Importance<\/jats:title>Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer strongly correlates with overall survival and has become the standard end point in neoadjuvant trials. However, there is controversy regarding whether the definition of pCR should exclude or permit the presence of residual ductal carcinoma in situ (DCIS).<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine the association of residual DCIS in surgical specimens after neoadjuvant chemotherapy for breast cancer with survival end points to inform standards for the assessment of pathologic complete response.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>The study team analyzed the association of residual DCIS after NAC with 3-year event-free survival (EFS), distant recurrence-free survival (DRFS), and local-regional recurrence (LRR) in the I-SPY2 trial, an adaptive neoadjuvant platform trial for patients with breast cancer at high risk of recurrence. This is a retrospective analysis of clinical specimens and data from the ongoing I-SPY2 adaptive platform trial of novel therapeutics on a background of standard of care for early breast cancer. I-SPY2 participants are adult women diagnosed with stage II\/III breast cancer at high risk of recurrence.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Participants were randomized to receive taxane and anthracycline-based neoadjuvant therapy with or without 1 of 10 investigational agents, followed by definitive surgery.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The presence of DCIS and EFS, DRFS, and LRR.<\/jats:p><\/jats:sec>Results<\/jats:title>The study team identified 933 I-SPY2 participants (aged 24 to 77 years) with complete pathology and follow-up data. Median follow-up time was 3.9 years; 337 participants (36%) had no residual invasive disease (residual cancer burden 0, or pCR). Of the 337 participants with pCR, 70 (21%) had residual DCIS, which varied significantly by tumor-receptor subtype; residual DCIS was present in 8.5% of triple negative tumors, 15.6% of hormone-receptor positive tumors, and 36.6% of ERBB2-positive tumors. Among those participants with pCR, there was no significant difference in EFS, DRFS, or LRR based on presence or absence of residual DCIS.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The analysis supports the definition of pCR as the absence of invasive disease after NAC regardless of the presence or absence of DCIS.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier NCT01042379<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamasurg.2022.4118","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T15:05:11Z","timestamp":1662563111000},"page":"1034","source":"Crossref","is-referenced-by-count":22,"title":["Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial"],"prefix":"10.1001","volume":"157","author":[{"given":"Marie","family":"Osdoit","sequence":"first","affiliation":[{"name":"Department of Surgery, University of California San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Yau","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of California San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Fraser","family":"Symmans","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy C.","family":"Boughey","sequence":"additional","affiliation":[{"name":"Department of Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl A.","family":"Ewing","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of California San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Balassanian","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunn-Yi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Krings","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M","family":"Wallace","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of California San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somaye","family":"Zare","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwole","family":"Fadare","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Lancaster","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine V.","family":"Godellas","sequence":"additional","affiliation":[{"name":"Department of Surgery, Loyola University Chicago Stritch School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Loyola University Chicago Stritch School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M","family":"Tuttle","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Klein","sequence":"additional","affiliation":[{"name":"Laboratory Medicine and Pathology, Masonic Cancer Center, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunati","family":"Sahoo","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina J.","family":"Hieken","sequence":"additional","affiliation":[{"name":"Department of Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi M.","family":"Carter","sequence":"additional","affiliation":[{"name":"Laboratory Medicine and Pathology, May Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beiyun","family":"Chen","sequence":"additional","affiliation":[{"name":"Laboratory Medicine and Pathology, May Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen","family":"Ahrendt","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Colorado Denver, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Tchou","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Feldman","sequence":"additional","affiliation":[{"name":"Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Tousimis","sequence":"additional","affiliation":[{"name":"Department of Surgery, Georgetown University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Zeck","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, Georgetown University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Jaskowiak","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husain","family":"Sattar","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpana M.","family":"Naik","sequence":"additional","affiliation":[{"name":"Department of Surgery, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Catherine","family":"Lee","sequence":"additional","affiliation":[{"name":"Comprehensive Breast Program, Moffitt Cancer Center, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilin","family":"Rosa","sequence":"additional","affiliation":[{"name":"Department of Pathology, Moffitt Cancer Center, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Khazai","sequence":"additional","affiliation":[{"name":"Department of Pathology, Moffitt Cancer Center, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara H.","family":"Rendi","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie E.","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ossama","family":"Tawfik","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Kansas, Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita M.","family":"Asare","sequence":"additional","affiliation":[{"name":"Quantum Leap Healthcare Collaborative, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Esserman","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of California San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita A.","family":"Mukhtar","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of California San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"soi220062r1","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","article-title":"Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.","volume":"16","author":"Fisher","year":"1998","journal-title":"J Clin Oncol"},{"issue":"2","key":"soi220062r2","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.1999.17.2.460","article-title":"Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.","volume":"17","author":"Kuerer","year":"1999","journal-title":"J Clin Oncol"},{"issue":"5","key":"soi220062r3","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1200\/JCO.2002.20.5.1304","article-title":"Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes.","volume":"20","author":"Rouzier","year":"2002","journal-title":"J Clin Oncol"},{"issue":"15","key":"soi220062r4","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/jnci\/dji206","article-title":"American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.","volume":"97","author":"Carey","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"soi220062r5","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.","volume":"26","author":"Rastogi","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9938","key":"soi220062r6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"10","key":"soi220062r7","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.6004\/jnccn.2017.0158","article-title":"Pathologic complete response after neoadjuvant chemotherapy and long-term outcomes among young women with breast cancer.","volume":"15","author":"Spring","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"soi220062r9","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/modpathol.2015.74","article-title":"Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.","volume":"28","author":"Provenzano","year":"2015","journal-title":"Mod Pathol"},{"issue":"12","key":"soi220062r10","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1038\/sj.bjc.6600616","article-title":"Prediction of outcome in locally advanced breast cancer by post-chemotherapy nodal status and baseline serum tumour markers.","volume":"87","author":"Brenner","year":"2002","journal-title":"Br J Cancer"},{"issue":"3","key":"soi220062r11","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/sj.bjc.6602950","article-title":"Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma.","volume":"94","author":"Jones","year":"2006","journal-title":"Br J Cancer"},{"issue":"19","key":"soi220062r12","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1200\/JCO.2006.08.2271","article-title":"Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.","volume":"25","author":"Mazouni","year":"2007","journal-title":"J Clin Oncol"},{"issue":"15","key":"soi220062r13","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"soi220062r14","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s12282-014-0524-4","article-title":"Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG.","volume":"22","author":"Kuroi","year":"2015","journal-title":"Breast Cancer"},{"issue":"1","key":"soi220062r15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/bjc.2015.426","article-title":"Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort.","volume":"114","author":"Hamy","year":"2016","journal-title":"Br J Cancer"},{"issue":"28","key":"soi220062r16","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"soi220062r17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1513750","article-title":"Adaptive randomization of neratinib in early breast cancer.","volume":"375","author":"Park","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"soi220062r18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1513749","article-title":"Adaptive randomization of veliparib-carboplatin treatment in breast cancer.","volume":"375","author":"Rugo","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"soi220062r19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/his.1991.19.issue-5","article-title":"Pathological prognostic factors in breast cancer. I. the value of histological grade in breast cancer: experience from a large study with long-term follow-up.","volume":"19","author":"Elston","year":"1991","journal-title":"Histopathology"},{"issue":"8","key":"soi220062r20","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/S0344-0338(11)81095-2","article-title":"Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. computer-assisted image analysis (QIC score) vs. subjective grading (IRS).","volume":"189","author":"Remmele","year":"1993","journal-title":"Pathol Res Pract"},{"issue":"31","key":"soi220062r21","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update.","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"soi220062r22","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer.","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"soi220062r23","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","article-title":"Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.","volume":"25","author":"Hudis","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"soi220062r24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00432-019-03083-y","article-title":"Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis.","volume":"146","author":"LeVasseur","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"soi220062r25","doi-asserted-by":"publisher","first-page":"R98","DOI":"10.1186\/bcr3559","article-title":"Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index.","volume":"15","author":"Ribelles","year":"2013","journal-title":"Breast Cancer Res"},{"issue":"13","key":"soi220062r26","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1200\/JCO.21.02062","article-title":"Mortality after late breast cancer recurrence in Denmark.","volume":"40","author":"Pedersen","year":"2022","journal-title":"J Clin Oncol"},{"key":"soi220062r8","unstructured":"US Food and Drug Administration. Guidance for industry: pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval. Accessed August 2, 2021. https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm305501.pdf has been redirected to https:\/\/www.fda.gov\/media\/83507\/download"}],"container-title":["JAMA Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/articlepdf\/2795850\/jamasurgery_osdoit_2022_oi_220062_1667884249.86513.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T16:06:04Z","timestamp":1668009964000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2795850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamasurg.2022.4118","relation":{},"ISSN":["2168-6254"],"issn-type":[{"value":"2168-6254","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}